The Department of Health and Human Services (HHS) under Secretary Robert F. Kennedy Jr. is poised to impose new restrictions on medically assisted suicide, a move that could reshape end-of-life care across the United States. According to internal documents obtained by The Guardian, the agency is considering federal actions that would limit access to drugs used in assisted dying, potentially overriding state laws that have legalized the practice.
Background on Medically Assisted Suicide in the US
Medically assisted suicide, also known as aid in dying, is currently legal in 10 states and the District of Columbia. These laws allow terminally ill patients with a prognosis of six months or less to request and self-administer lethal medication prescribed by a physician. The practice has been a subject of intense debate, with supporters citing personal autonomy and opponents raising ethical and safety concerns.
HHS's Planned Actions
The HHS memo, dated July 8, outlines a strategy to use the Controlled Substances Act to reclassify drugs commonly used in assisted suicide, such as secobarbital and pentobarbital, as Schedule I substances. This would effectively ban their use for this purpose, as Schedule I drugs are deemed to have no accepted medical use. The move would directly challenge state laws and could trigger a legal battle over states' rights versus federal authority.
Secretary Kennedy, a longtime critic of medically assisted suicide, has argued that the practice is incompatible with the administration's pro-life stance. In a statement, he said, "We must protect the most vulnerable among us, including those facing terminal illness. Our policies should prioritize compassionate care, not hastened death." The HHS plans to seek public comment before finalizing any rule changes.
Impact on Patients and Providers
If implemented, the restrictions would have immediate consequences for patients who rely on assisted suicide as an end-of-life option. Dr. Sarah Johnson, a palliative care specialist in Oregon, said, "This would be devastating for my patients. They have exhausted all treatment options and want to die with dignity. Taking away this choice is cruel." The number of assisted suicide deaths has been rising, with Oregon reporting 371 such deaths in 2025, a 15% increase from the previous year.
Healthcare providers who prescribe these medications could face legal risks under federal law, potentially leading to investigations or loss of licensure. The American Medical Association has expressed concern, urging the HHS to consider the impact on patient care and physician-patient relationships.
Legal and Political Reactions
The proposed action has drawn sharp criticism from advocacy groups like Compassion & Choices, which vowed to challenge any federal overreach in court. President of the organization, Kim Callinan, said, "This is a direct attack on the rights of terminally ill patients and their families. We will fight this with every legal tool available." Meanwhile, conservative groups have praised the move, with the Family Research Council calling it a "victory for life."
The Trump administration's stance aligns with broader efforts to limit access to assisted suicide, which has been a priority for religious and anti-abortion activists. However, legal experts note that the federal government's authority to regulate medical practice is limited, and states may argue that assisted suicide is a matter of public health and safety within their jurisdiction.
Looking Ahead
The HHS is expected to publish a notice of proposed rulemaking in the Federal Register within weeks, initiating a 60-day comment period. The final rule could be issued before the end of the year, setting the stage for a protracted legal battle. As the debate unfolds, patients and providers are left in uncertainty, highlighting the deep divisions over end-of-life care in America.
